[Sarcoidosis].
| Autor: | Jeny F; AP-HP, service de pneumologie, hôpital Avicenne, Bobigny, France EA2363, « Hypoxie et Poumon », Paris-13 SMBH, Bobigny, France., Valeyre D; AP-HP, service de pneumologie, hôpital Avicenne, Bobigny, France EA2363, « Hypoxie et Poumon », Paris-13 SMBH, Bobigny, France. |
|---|---|
| Jazyk: | francouzština |
| Zdroj: | La Revue du praticien [Rev Prat] 2019 Jan; Vol. 69 (1), pp. 83-95. |
| Abstrakt: | Sarcoidosis. Sarcoidosis is a rare, systemic granulomatosis disease of unknown cause. In almost all cases sarcoidosis affects the lung and the lymphatic system. Diagnosis and treatment can be difficult because of highly variable clinicals and evolutions presentations. Clinician must track organ dysfunctions that may be life-threatening (pulmonary, cardiac involment) or that impact functional prognosis (neurological, ophthalmic, renal) and qualified as «dangerous». It is important also to evaluate and take care of persistent signs of discomfort, which can severely affect patients' quality of life. The treatment of sarcoidosis is not systematic, but if necessary, corticosteroids, with notable side effects are the first intention treatment. Second- and third-line treatments are immunosuppressants and TNF antagonists, respectively. Competing Interests: F. Jeny déclare avoir été prise en charge lors de congrès par Oxyvie. D. Valeyre déclare des liens ponctuels avec Bohringer Ingelheim, Roche et Astra Zenecca. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|